Search Results
Oct 29, 2025, 07:13 ET Opera Reports Third Quarter 2025 Results Ahead of Expectations, Raises Full-Year Guidance Ranges for Both Revenue and Adjusted EBITDA
adjusted net income as net income excluding (i) profit (loss) from discontinued operations, (ii) gain (loss) on investments in unconsolidated entities, (iii) non-recurring expenses, (iv) impairment of non-financial assets, (v) amortization of acquired intangible assets, (vi) share-based compensation expenses,
More news about: Opera Limited
Oct 29, 2025, 07:00 ET BANKFIRST CAPITAL CORPORATION Reports Third Quarter 2025 Earnings of $5.20 Million
"Basel III Rules," apply to both depository institutions and (subject to certain exceptions not applicable to the Company) their holding companies. The Basel III Rules also establish a "capital conservation buffer" of 2.5% above the regulatory minimum risk-based capital requirements. The Basel III minimum
More news about: BankFirst Capital Corporation
Oct 29, 2025, 07:00 ET UCB to unveil new data for RYSTIGGO® (rozanolixizumab-noli) and ZILBRYSQ®(zilucoplan) for gMG at the 2025 AANEM Annual Meeting and MGFA Scientific Session
AANEM session I & III and MGFA SS(Poster)
More news about: UCB
Oct 29, 2025, 07:00 ET Stepan Reports Third Quarter 2025 Results
Table III
More news about: Stepan Company
Oct 29, 2025, 06:51 ET Timken Reports Third-Quarter 2025 Results
reorganization charges (including items recorded in cost of products sold) relate to: (i) plant closures; (ii) the rationalization of certain plants; (iii) severance related to cost reduction initiatives; (iv) impairment of assets; and (v) related depreciation and amortization. The Company re-assesses its
More news about: The Timken Company
Oct 29, 2025, 06:31 ET Cat Financial Announces Third-Quarter 2025 Results
resulting increases to our cost of borrowing and adverse effects on our cost of funds, liquidity, competitive position and access to capital markets; (iii) changes in interest rates, currency fluctuations or market liquidity conditions; (iv) an increase in delinquencies, repossessions or net losses of our
More news about: Cat Financial
Oct 29, 2025, 06:30 ET Hyperscale Data Expands Bitcoin Mining Capacity with Order of 2,000 Bitmain S21 Pro Bitcoin Miners
purchase of S21 Pro's reinforces our commitment to the digital asset space, and Bitcoin specifically," stated Milton "Todd" Ault III, Executive Chairman of Hyperscale Data. "By housing our Bitcoin mining operation and NVIDIA AI clusters under the same roof, we are maximizing
More news about: Hyperscale Data Inc.
Oct 29, 2025, 06:30 ET Caterpillar Reports Third-Quarter 2025 Results
demonstrated by the company's Rolling 3 Month Retail Sales Statistics filed in a Form 8-K on Wednesday, Oct. 29, 2025. iii. Information on non-GAAP financial measures is included in the appendix on pages 12 and 13.
More news about: Caterpillar Inc.
Oct 29, 2025, 06:05 ET Avantor® Reports Third Quarter 2025 Results
Adjusted Operating Income is our net income or loss adjusted for the following items: (i) interest expense, (ii) income tax expense, (iii) amortization of acquired intangible assets, (iv) losses on extinguishment of debt, (v) charges associated with the impairment of certain assets, (vi)
More news about: Avantor and Financial News
Oct 29, 2025, 06:00 ET NLS Pharmaceutics Ltd. Announces 1-for-10 Reverse Share Split and Name Change in Connection with Proposed Merger with Kadimastem
(ii) 1,060,574 total outstanding common shares, par value CHF 0.05, issuable upon the exercise of pre-funded warrants issued as Merger consideration, (iii) 13,778 total outstanding preferred shares, par value CHF 0.05, and (iv) 58,320 total outstanding preferred participation certificates, par value CHF
More news about: NLS Pharmaceutics Ltd.; Kadimastem Ltd.
Oct 29, 2025, 06:00 ET Theravance Biopharma to Present Data on Ampreloxetine at the 36th International Symposium on The Autonomic Nervous System
Theravance Biopharma U.S.Poster number: 15 Poster title: Enrollment strategies in a phase III trial for MSA-related nOH: insights from global investigatorsPresenter: Molly Szpyhulsky, MBA, BSN, RN; Theravance Biopharma U.S.Poster
More news about: Theravance Biopharma, Inc.
Oct 29, 2025, 03:52 ET UPM Interim Report Q3 2025: UPM business portfolio delivered resilient performance in weak markets
UPM Biofuels produced good volumes and the renewable fuel market prices continued recovering. The EU level renewable energy directive (RED III) is expected to support demand and valuation for advanced renewable fuels, pending implementation at the national level legislation.
More news about: UPM-Kymmene Oyj
Oct 29, 2025, 02:27 ET Photocure ASA: Results for the third quarter of 2025
accounts in the U.S. at the end of the quarter, an increase of 23% versus the second quarter of 2024. Across Europe, a total of 49 Olympus Visera Elite III blue light cystoscopy (BLC) capable systems were installed since the launch in Q1 2025. Total revenues ended at NOK 135.0 million
More news about: Photocure
Oct 29, 2025, 02:21 ET Photocure ASA: Results for the third quarter of 2025
accounts in the U.S. at the end of the quarter, an increase of 23% versus the second quarter of 2024. Across Europe, a total of 49 Olympus Visera Elite III blue light cystoscopy (BLC) capable systems were installed since the launch in Q1 2025. Total revenues ended at NOK 135.0 million
More news about: Photocure
Oct 29, 2025, 01:00 ET LEVI & KORSINSKY ISSUES CORRECTION: Securities Fraud Class Action Against Savara Inc.
regarding MOLBREEVI's chemistry, manufacturing, and/or controls; (ii) accordingly, FDA was unlikely to approve the MOLBREEVI BLA in its current form; (iii) foregoing made it unlikely that Savara would complete its submission of the MOLBREEVI BLA within the timeframe it had represented to investors; (iv)
More news about: Levi & Korsinsky, LLP
Oct 29, 2025, 01:00 ET LEVI & KORSINSKY ISSUES CORRECTION: Securities Fraud Class Action Against Fluor Corporation
hesitation around economic uncertainty, was having, or was likely to have, a significant negative impact on the Company's business and financial results; (iii) accordingly, Fluor's financial guidance for FY 2025 was unreliable and/or unrealistic, the effectiveness of the Company's risk mitigation strategy was
More news about: Levi & Korsinsky, LLP
Oct 29, 2025, 00:05 ET SI GROUP ABRE NOVO CENTRO DE INOVAÇÃO
às instalações e um discurso de Sua Majestade, Lorde-Tenente de Staffordshire, Professora Elizabeth Barnes CBE, em nome de Sua Majestade, Rei Charles III. Representantes da imprensa e profissionais do setor foram convidados a participar. Sobre o SI GroupO
More news about: SI Group, Inc.
Oct 29, 2025, 00:00 ET SI GROUP ABRE UN NUEVO CENTRO DE INNOVACIÓN
de la lord teniente de Staffordshire, la profesora en Educación Basada en Competencias (CBE) Elizabeth Barnes, en nombre de su majestad el rey Carlos III. Se invitó a asistir a representantes de los medios de comunicación y profesionales de la industria. Acerca
More news about: SI Group, Inc.
Oct 28, 2025, 23:38 ET SI GROUP OUVRE UN NOUVEAU CENTRE D'INNOVATION
et un discours d'ouverture prononcé par le Lord-Lieutenant de Staffordshire, la professeure Elizabeth Barnes CBE, au nom de Sa Majesté le roi Charles III. Les représentants des médias et les professionnels du secteur ont été invités à y participer. À propos
More news about: SI Group, Inc.
Oct 28, 2025, 23:32 ET SI GROUP ERÖFFNET NEUES INNOVATIONSZENTRUM
Einrichtung sowie eine Grundsatzrede des Lord-Lieutenants von Staffordshire, Professorin Elizabeth Barnes CBE, im Namen Seiner Majestät König Charles III. Medienvertreter und Fachleute aus der Branche waren zur Teilnahme eingeladen. Informationen zur SI GroupDie
More news about: SI Group, Inc.
Oct 28, 2025, 20:33 ET CORRECTION: Securities Fraud Class Action Against Dow Inc.
pricing pressures, softening global sales and demand for the Company's products, and an oversupply of products in the Company's global markets; and (iii) as a result, defendants' public statements were materially false and misleading at all relevant times. WHAT'S
More news about: Levi & Korsinsky, LLP
Oct 28, 2025, 18:00 ET BLADEX ANNOUNCES NET PROFITS OF $55.0 MILLION OR $1.48 PER SHARE IN 3Q25 AND $170.9 MILLION OR $4.60 PER SHARE IN 9M25
period. Tier 1 Capital ratio is calculated according to Basel III capital adequacy guidelines, and as a percentage of risk-weighted assets. Risk-weighted assets are estimated based on Basel III capital adequacy guidelines, utilizing internal-ratings based approach or "IRB" for credit
More news about: Banco Latinoamericano de Comercio Exterior, S.A. (Bladex)
Oct 28, 2025, 17:45 ET FIBRA Prologis Announces Third Quarter 2025 Earnings Results
international, regional and local economic climates, (ii) changes in financial markets, trade relations, interest rates and foreign currency exchange rates, (iii) increased or unanticipated competition for our properties, (iv) risks associated with acquisitions, dispositions and development of properties, (v)
More news about: FIBRA Prologis
Oct 28, 2025, 17:45 ET FIBRA Prologis Anuncia sus Resultados Financieros del Tercer Trimestre de 2025
situación económica internacional regional y local, (ii) los cambios en los mercados financieros, tasas de interés y tipos de cambio de moneda extranjera, (iii) aumento en, o surgimiento de, competencia respecto de nuestras propiedades, (iv) los riesgos asociados con adquisiciones, enajenación y desarrollo de
More news about: FIBRA Prologis
Oct 28, 2025, 17:45 ET FIBRA Prologis Anuncia sus Resultados Financieros del Tercer Trimestre de 2025
situación económica internacional regional y local, (ii) los cambios en los mercados financieros, tasas de interés y tipos de cambio de moneda extranjera, (iii) aumento en, o surgimiento de, competencia respecto de nuestras propiedades, (iv) los riesgos asociados con adquisiciones, enajenación y desarrollo de
More news about: FIBRA Prologis